These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8093844)

  • 1. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties.
    Lagakos SW
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S22-5. PubMed ID: 8093844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate markers in AIDS and cancer trials.
    Fleming TR
    Stat Med; 1994 Jul 15-30; 13(13-14):1423-35; discussion 1437-40. PubMed ID: 7973222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 counts as surrogate markers for progression to AIDS.
    Harris PJ
    Ann Intern Med; 1994 Jan; 120(1):88. PubMed ID: 7902690
    [No Abstract]   [Full Text] [Related]  

  • 4. CD4 counts as surrogate markers for progression to AIDS.
    Hirschel B
    Ann Intern Med; 1994 Jan; 120(1):87; author reply 88. PubMed ID: 7902687
    [No Abstract]   [Full Text] [Related]  

  • 5. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection.
    Machado SG; Gail MH; Ellenberg SS
    J Acquir Immune Defic Syndr (1988); 1990; 3(11):1065-73. PubMed ID: 1976795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1123-33. PubMed ID: 10954887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review.
    Stein DS; Korvick JA; Vermund SH
    J Infect Dis; 1992 Feb; 165(2):352-63. PubMed ID: 1346152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 counts as surrogate markers for progression to AIDS.
    Phillips AN; Sabin CA
    Ann Intern Med; 1994 Jan; 120(1):87-8. PubMed ID: 7902689
    [No Abstract]   [Full Text] [Related]  

  • 10. CD4 counts as surrogate markers for progression to AIDS.
    Nightingale SD
    Ann Intern Med; 1994 Jan; 120(1):87; author reply 88. PubMed ID: 7902688
    [No Abstract]   [Full Text] [Related]  

  • 11. Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts.
    Phillips AN; Sabin CA; Elford J; Bofill M; Janossy G; Lee CA
    Am J Epidemiol; 1993 Nov; 138(10):870-8. PubMed ID: 7901990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific.
    Krämer A; Biggar RJ; Hampl H; Friedman RM; Fuchs D; Wachter H; Goedert JJ
    Am J Epidemiol; 1992 Jul; 136(1):71-80. PubMed ID: 1384311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.
    Levacher M; Tallet S; Dazza MC; Dournon E; Rouveix B; Pocidalo JJ
    Clin Exp Immunol; 1990 Aug; 81(2):177-82. PubMed ID: 1696859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate end points in clinical trials.
    Ellenberg SS
    BMJ; 1991 Jan; 302(6768):63-4. PubMed ID: 1671650
    [No Abstract]   [Full Text] [Related]  

  • 15. Surrogate markers in AIDS: where are we? Where are we going?
    Lagakos SW; Hoth DF
    Ann Intern Med; 1992 Apr; 116(7):599-601. PubMed ID: 1347443
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV surrogate markers weighed.
    Cotton P
    JAMA; 1991 Mar; 265(11):1357, 1361-2. PubMed ID: 1671883
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of the risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort Study.
    Saah AJ; Muñoz A; Kuo V; Fox R; Kaslow RA; Phair JP; Rinaldo CR; Detels R; Polk BF
    Am J Epidemiol; 1992 May; 135(10):1147-55. PubMed ID: 1352940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate markers of disease studied as means of determining AIDS drugs' effectiveness.
    Cotton P
    JAMA; 1990 Nov; 264(18):2362, 2365. PubMed ID: 1977933
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surrogate markers in AIDS.
    Nuako K
    Ann Intern Med; 1992 Oct; 117(7):619. PubMed ID: 1355955
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.